Matthew Krebs, MB, PhD, Reviews the Next Steps for Subcutaneous Amivantamab in Solid Tumors


Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.

CancerNetwork® spoke with Matthew Krebs, MB, PhD, clinical senior lecturer in Experimental Cancer Medicine at the University of Manchester and Honorary Consultant in Medical Oncology at the Christie Hospital in the United Kingdom, during the American Association for Cancer Research (AACR) 2022 Annual Meeting about increasing the subcutaneous dose of amivantamab (Rybrevant) in future research. Previous research was completed during the phase 1 PALOMA trial (NCT04606381) in which patients with solid malignancies were administered the agent to determine its safety and feasibility.


The next steps are to go up on the dosing [of amivantamab] that we’re giving subcutaneously. The pharmacokinetic data from this study, which was also a primary end point, showed that the maximum concentration was achieved in 2 to 3 days. We did get a higher exposure when we co-administered with the recombinant human PH20, as we might have expected. We’ve now decided that we will move forward with the coformulation with the recombinant human PH20, and the higher concentration of the drug because we can administer that in just a few minutes.

It’s quite an easy treatment to deliver, we can do it manually, and it’s safe. The pharmacokinetic data also showed us that the exposure we keep getting with the subcutaneous administration…is only 65% of the intravenous dosing, which you might expect. The next step would be to go to the next cohort of patients and treat the subcutaneous dosing at a higher level. We’re trying to get the exposure [similar to] that of the intravenous dose. We’ll also want to collect ongoing data as to infusion-related reactions as we go up on that dose, and to make sure it remains safe to administer the full dose on site on day 1.

These are very promising preliminary results, but it’s only in 33 patients so far. We’re very excited about the potential for this drug to be given subcutaneously. It will certainly help in the clinic if we can shorten that infusion time as we look to having less infusion-related reactions. It is a very positive step forward for the program. We look forward to ongoing data as we take this further.


Krebs MG, Johnson ML, Cho BC, et al. Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study. Presented at the American Association for Cancer Research 2022 Annual Meeting. New Orleans, LA. April 8-13, 2022. Abstract CT198 / 23.

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content